Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | HTR1B | P28222 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | TNF | P01375 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9217674 | 0.82 | TRPA1 (0.41) | TRPA1ATMCYP1A2CYP2A6TSHR | |
| SCHEMBL10440548 | 0.80 | TRPA1 (0.39) | TRPA1ATMCYP1A2CYP2A6TSHR | |
| SCHEMBL7033569 | 0.78 | TRPA1 (0.38) | TRPA1ATMCYP1A2CYP2A6TSHR | |
| SCHEMBL10523368 | 0.78 | TRPA1 (0.38) | TRPA1ATMCYP1A2CYP2A6TSHR | |
| SCHEMBL9343766 | 0.78 | TRPA1 (0.38) | TRPA1ATMCYP1A2CYP2A6TSHR | |
| SCHEMBL6340796 | 0.78 | TRPA1 (0.43) | TRPA1ATMCYP1A2CYP2A6TSHR | |
| SCHEMBL1469568 | 0.76 | HTR1B (0.33) | TRPA1ATMTSHRSMN1; SMN2HTR1B | |
| SCHEMBL1470830 | 0.75 | TRPA1 (0.40) | TRPA1ATMCYP1A2CYP2A6TSHR | |
| SCHEMBL11206939 | 0.75 | TRPA1 (0.36) | TRPA1ATMCYP1A2ALDH1A1TDP1 | |
| SCHEMBL113990 | 0.75 | TRPA1 (0.42) | TRPA1ATMCYP1A2CYP2A6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113244761-B | Mixed silicone oil for capturing acid gas through phase change and preparation method thereof | 昆明理工大学 | 2023-07-07 | — | — | CN | claimed |
| CN-113244761-B | Mixed silicone oil for capturing acid gas through phase change and preparation method thereof | 昆明理工大学 | 2023-07-07 | — | — | CN | disclosed |
| CN-113244761-A | Mixed silicone oil for capturing acid gas through phase change and preparation method thereof | 昆明理工大学 | 2021-08-13 | — | — | CN | disclosed |
| CN-111405980-A | Article comprising a surface coating and method for producing the same | 麦克斯特里尔有限公司 | 2020-07-10 | — | — | CN | disclosed |
| US-8952247-B2 | Photoelectric converter and solar cell using the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2015-02-10 | — | — | US | disclosed |
| US-8552289-B2 | — | — | 2013-10-08 | — | — | US | disclosed |
| EP-1644384-B1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF ENTECAVIR | BRISTOL MYERS SQUIBB CO (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2433941-A1 | Process for isolating the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | Bristol-Myers Squibb Company (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20110097365-A1 | S-TRIAZINE DERIVATIVES CONTAINING AT LEAST TWO PARTICULAR SILANE AMINOBENZOATE OR SILANE AMINOBENZAMIDE GROUPS; PHOTOPROTECTIVE COSMETIC COMPOSITIONS CONTAINING THESE DERIVATIVES; USES OF THE SAID S-TRIAZINE DERIVATIVES | L'OREAL (FR) | 2011-04-28 | — | — | US | disclosed |
| US-20110005597-A1 | PHOTOELECTRIC CONVERTER AND SOLAR CELL USING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-1594880-A1 | PHOTOPROTECTIVE COMPOSITIONS BASED ON METHYLTRIALKYLSILANES CONTAINING A CINNAMATE, CINNAMAMIDE, BENZALMALONAMIDE OR BENZALMALONATE FUNCTION | L'OREAL (FR) | 2005-11-16 | — | — | EP | disclosed |
| US-20040192912-A1 | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-30 | — | — | US | disclosed |
| WO-2004067539-A1 | PHOTOPROTECTIVE COMPOSITIONS BASED ON METHYLTRIALKYLSILANES CONTAINING A CINNAMATE, CINNAMAMIDE, BENZALMALONAMIDE OR BENZALMALONATE FUNCTION | L'OREAL (FR) | 2004-08-12 | — | — | WO | disclosed |
| WO-2004052310-A2 | PROCESS AND INTERMEDIATES FOR SYNTHESIS ENTECAVIR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-24 | — | — | WO | disclosed |
| US-6608081-B2 | Treating pneumonia | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-08-19 | — | — | US | disclosed |
| US-20020161029-A1 | Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-10-31 | — | — | US | disclosed |
| CN-1216921-A | Method for inducing vascular cell adhesion molecule-1 and treating chronic inflammatory diseases using 2, 6-dialkyl-4-silyl-phenols | HOECHST MARION ROUSSEL INC (US) | 1999-05-19 | — | — | CN | disclosed |
| EP-0770084-A1 | SILYLMETHYL-ANILINE DERIVATIVES, METHODS OF PREPARATION AND USE THEREOF AS DRUGS | PIERRE FABRE MEDICAMENT (FR) | 1997-05-02 | — | — | EP | disclosed |
| WO-1996001830-A1 | SILYLMETHYL-ANILINE DERIVATIVES, METHODS OF PREPARATION AND USE THEREOF AS DRUGS | PIERRE FABRE MEDICAMENT (FR) | 1996-01-25 | — | — | WO | disclosed |
| EP-0464852-A1 | Novel 2,6-di-alkyl-4-silyl-phenols as antiatherosclerotic agents and as antioxidants | MERRELL PHARMACEUTICALS INC. (US) | 1992-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161029-A1 | Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods | OXA1L, NDUFS3, CYCS | TRPA1 3049/4885ATM 2666/4885CYP1A2 169/4885 |
| US-20040192912-A1 | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | SAMHD1, NUDT1, ENTPD1 | TRPA1 4866/4885ATM 4772/4885CYP1A2 2692/4885 |
| US-20110097365-A1 | S-TRIAZINE DERIVATIVES CONTAINING AT LEAST TWO PARTICULAR SILANE AMINOBENZOATE OR SILANE AMINOBENZAMIDE GROUPS; PHOTOPROTECTIVE COSMETIC COMPOSITIONS CONTAINING THESE DERIVATIVES; USES OF THE SAID S-TRIAZINE DERIVATIVES | TST, STS, TYR | TRPA1 300/4885ATM 507/4885CYP1A2 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.